IP receptor is short for Prostaglandin I2 receptor or prostacyclin receptor. Selexipag is an oral medication used for the treatment of pulmonary arterial hypertension (PAH). It is useful as both primary treatment and as add on treatment to background therapy as shown by the GRIPHON Trial .
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33.